Feed Top Reports Pricing

⌘K

06:16:37·1726d

ANALYSTRating

HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target

AZRX· AzurRx BioPharma, Inc.

Health Care

Original source

Companies

AZRX
AzurRx BioPharma, Inc.
Health Care

Recent analyst ratings

Aug 2UpdateHC Wainwright & Co.$2.00

Related

SEC1668d
AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events
SEC1675d
AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
PR1675d
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
SEC1682d
AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
PR1683d
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
INSIDER1683d
SEC Form 4 filed by Coelho Mary Theresa
SEC1684d
AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR1684d
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022